Skip to content
Facebook Twitter Linkedin
InMed-logo-01
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
    • BayMedica Cannabinoid Biosynthesis
    • Rare Cannabinoid Ingredients
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
Menu
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
    • BayMedica Cannabinoid Biosynthesis
    • Rare Cannabinoid Ingredients
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
InMed Acquiring BayMedica
InMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare Cannabinoids
Read press release
Game-Changing Cannabinoid Manufacturing System
IntegraSyn™ is InMed’s integrated cannabinoid manufacturing system to efficiently produce bio-identical cannabinoids.
Learn More
Leader in the Therapeutic Development of Cannabinol (CBN)
InMed is the first company to advance the rare cannabinoid, cannabinol (CBN), into a clinical trial as a potential therapeutic to treat disease.
Learn More
INM-755 for Epidermolysis Bullosa
InMed has initiated its Phase 2 clinical trial of INM-755, a cannabinol topical cream in development for the treatment of epidermolysis bullosa, a devastating genetic skin disease.
Learn More
Rare Cannabinoids for Ocular Diseases
INM-088 is a cannabinol formulation under development for glaucoma. Preclinical studies indicate CBN’s potential to provide neuroprotection as well as reduce intraocular pressure in the eye.
Learn More

Unlocking the Potential of Rare Cannabinoids

Expertise in the pharmaceutical development of rare cannabinoids

InMed is a clinical-stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates to treat several diseases with high unmet medical needs.

Programs for skin and ocular disease

Two of InMed’s most advanced programs focus on rare cannabinoid formulations for skin and ocular diseases. Cannabinol (CBN) is the active pharmaceutical ingredient (API) in InMed’s two lead programs for epidermolysis bullosa and glaucoma. InMed has commenced a Phase 2 clinical trial of INM-755 (cannabinol) cream for epidermolysis bullosa, a devastating, rare genetic skin disease. InMed’s second program, INM-088, is a CBN-based product being developed as a topical ocular formulation for glaucoma and is currently in preclinical studies. Learn more about our programs in epidermolysis bullosa and glaucoma.

A goal to deliver safe and effective cannabinoid treatments

InMed’s preclinical studies of cannabinol (CBN) demonstrated an excellent safety profile. In preclinical studies, CBN showed the potential for therapeutic benefit over other cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD). The findings from these extensive studies supported the advancement of INM-755 cream as an investigational treatment for epidermolysis bullosa (EB) into Phase 1 clinical studies in healthy volunteers. Two Phase 1 studies have been completed and Clinical Trial Applications have been filed in several countries as part of a global Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa. 

learn More

Integrated cannabinoid manufacturing system to produce pharmaceutical-grade, bio-identical cannabinoids

While rare cannabinoids may hold tremendous potential as new treatments for diseases with high unmet medical needs, it is not economically feasible to extract and purify most of them directly from the plant due to the very low quantities available.

IntegraSynTM, InMed’s integrated cannabinoid manufacturing system, uses multiple standard pharmaceutical processes to enable the production of cannabinoids with bio-identical structures as compared to those found in nature.

The IntegraSynTM manufacturing approach has been able to achieve a level of 5 g/L cannabinoid yield, a commercially viable yield that significantly exceeds currently reported industry yields.

learn More
Click to enlarge

Successful track record

InMed aims to transform patients’ lives by developing safe and effective cannabinoid-based therapeutics across a broad spectrum of diseases with high unmet medical needs.

Since our formation in 2014, we have fortified our capital position, assembled a world class leadership team with a successful track record in drug development, strengthened our potentially game-changing technologies, and advanced our novel, cannabinoid-based pipeline of drug candidates.

Today, InMed is acutely focused on building a technologically advanced cannabinoid pharmaceutical company unlike any other.

learn More

Latest News

InMed Announces Publication of Peer-Reviewed Study Showing the Anti-Inflammatory Potential of Rare Cannabinoids in Skin Conditions

March 13, 2023
Learn More

InMed to Participate in Upcoming Investor Events

March 6, 2023
Learn More

InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update

February 17, 2023
Learn More

InMed Submits Form 12b-25

February 9, 2023
Learn More

InMed Provides Business Update and Milestones for 2023

January 10, 2023
Learn More

InMed Announces Results of 2022 Annual General Meeting

December 15, 2022
Learn More
See all news

Investor Alerts

Sign up to receive news releases from InMed Pharmaceuticals.
SIGN UP


INM-755

A cannabinol (CBN) topical cream in Phase 2 clinical trials for epidermolysis bullosa
Learn More

INM-088

A cannabinol (CBN) formulation in preclinical development for the treatment of glaucoma
Learn More

IntegraSyn™

InMed’s flexible, integrated cannabinoid manufacturing system to efficiently produce pharmaceutical-grade, bio-identical cannabinoids.
Learn More
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Pharmaceutical

  • Cannabinoids in Development
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • Neurodegenerative Disease
  • Novel Cannabinoid Analogs

MANUFACTURING

  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing
  • BayMedica Cannabinoid Biosynthesis
  • Rare Cannabinoid Ingredients

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM
  • Filings
  • Presentations
  • Media

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisory Board
  • Partners and Collaborators
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2023 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*
Consent